Dan Kracov, Derek Stoldt Discuss Life Sciences Deal Trends at JPM 2026

Dan Kracov, chair of the firm's Global Life Sciences Industry group, and Derek Stoldt, co-chair of the firm's Corporate and Finance group and co-head of the Life Sciences Transactions practice, were recently interviewed by Law360 at the 2026 J.P. Morgan Healthcare Conference. They shared insights on this year’s conference, reflected on healthcare dealmaking in 2025, and outlined what they’re monitoring in 2026.

In an article covering how this year’s conference is unfolding, Derek observed that, unlike some years when there was clear pressure for companies to time deal announcements around JPM, this year’s focus seemed to be doing “the right deals at the right time.”

In a subsequent story on what JPM signals for healthcare dealmaking in 2026, Derek said he expects more “nuts-and-bolts” pharmaceutical and biotechnology transactions going forward.

“If you look at most pharmaceutical companies, Big Pharma, the majority of their research and development comes through in-licensing,” he noted.

Dan added that in addition to continued licensing activity, he expects an “avalanche” of M&A – “mostly ‘A” – in the coming months.

Read the Law360 article, “Dispatch From JPM: Fewer Health Deals Don't Dampen Mood” (subscription required).

Read the Law360 article, “What JPM Tells Us About Healthcare Deals In 2026” (subscription required).